MedTrace Logo

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

NCT00543959 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 346

Last updated 2015-06-23

No results posted yet for this study

Summary

A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

MK0533

Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.

DRUG

Comparator: Placebo (unspecified)

MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.

DRUG

Comparator: pioglitazone

pioglitazone 45mg. Study period is a total of 24 wks.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-08-31
Completion
2007-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00543959 on ClinicalTrials.gov